Greenspring Advisors LLC Acquires Shares of 4,296 Novartis AG $NVS

Greenspring Advisors LLC acquired a new stake in Novartis AG (NYSE:NVS) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 4,296 shares of the company’s stock, valued at approximately $592,000.

Other institutional investors have also recently bought and sold shares of the company. Arlington Trust Co LLC bought a new stake in Novartis in the 4th quarter valued at about $25,000. Measured Wealth Private Client Group LLC bought a new stake in Novartis in the 3rd quarter valued at about $33,000. South Plains Financial Inc. boosted its holdings in Novartis by 39.0% in the 3rd quarter. South Plains Financial Inc. now owns 271 shares of the company’s stock valued at $35,000 after purchasing an additional 76 shares during the period. Aventura Private Wealth LLC bought a new stake in Novartis in the 4th quarter valued at about $45,000. Finally, Cornerstone Planning Group LLC boosted its holdings in Novartis by 15,950.0% in the 4th quarter. Cornerstone Planning Group LLC now owns 321 shares of the company’s stock valued at $47,000 after purchasing an additional 319 shares during the period. Institutional investors own 13.12% of the company’s stock.

Analyst Upgrades and Downgrades

NVS has been the subject of a number of recent research reports. TD Cowen reissued a “hold” rating on shares of Novartis in a report on Tuesday, February 17th. Weiss Ratings cut shares of Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research report on Wednesday, April 29th. Morgan Stanley boosted their target price on shares of Novartis from $143.00 to $170.00 and gave the company an “overweight” rating in a research report on Thursday, March 26th. Citigroup restated a “buy” rating on shares of Novartis in a research report on Thursday, February 5th. Finally, Wall Street Zen cut shares of Novartis from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $141.20.

Novartis Price Performance

Shares of NYSE:NVS opened at $148.39 on Friday. The firm has a 50 day moving average of $149.60 and a 200-day moving average of $147.26. The stock has a market capitalization of $283.14 billion, a PE ratio of 21.26, a PEG ratio of 2.52 and a beta of 0.46. The company has a current ratio of 0.85, a quick ratio of 0.65 and a debt-to-equity ratio of 0.96. Novartis AG has a 12 month low of $112.34 and a 12 month high of $170.46.

Novartis (NYSE:NVS) last issued its earnings results on Monday, April 27th. The company reported $1.99 EPS for the quarter, missing the consensus estimate of $2.11 by ($0.12). The firm had revenue of $13.52 billion during the quarter, compared to analyst estimates of $13.44 billion. Novartis had a net margin of 24.87% and a return on equity of 38.82%. Novartis’s quarterly revenue was down .9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.28 earnings per share. On average, equities research analysts predict that Novartis AG will post 8.84 EPS for the current fiscal year.

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.